LEGN vs PTCT: fair value comparison
Legend Biotech Corporation and PTC Therapeutics, Inc. · Updated 2026-10-19
LEGN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. PTCT is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, LEGN currently ranks higher by quality score.
| LEGN | PTCT | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $18.48 | $59.24 |
| 12-month range | $16.65–$36.28 | $59.24–$89.55 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #85 of 301 Healthcare | #87 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: LEGN fair value analysis · PTCT fair value analysis